Portable ADA Detection Device Using Lateral Flow Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack standardization and unification in detecting antibodies against therapeutic drugs (ADAs), leading to challenges in comparing immunogenicity across different biotherapeutics and therapeutic drugs, which can impact efficacy and safety, and are not suitable for point-of-care or patient self-testing due to complexity and variability in assays and sample handling.
Innovation Solution
Development of portable devices for ADA testing that enable standardized detection of antibodies across various therapeutic drugs, using lateral flow technology and potentially electrochemiluminescence or carbon nanotube biosensors, allowing for point-of-care and self-testing, and providing access to a database for comprehensive analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional ADA detection assays are used, then detection capability is achieved, but device complexity and difficulty of operation increase, making them unsuitable for point-of-care or self-testing
Solution Approach 1:
The device is segmented into distinct functional modules: a sample pad for specimen reception, a conjugate pad containing labeled detection reagents, a membrane with immobilized capture reagents, and an absorbent pad. This segmentation allows each component to perform a specific function independently, simplifying operation while maintaining detection capability.
Solution Approach 2:
The patent introduces a bridging assay format using an intermediary detection reagent that connects the sample antibodies to the solid-phase capture reagents. This intermediary approach simplifies the detection mechanism and enables standardized testing across different therapeutic drugs without requiring complex drug-specific assay development.
2Measurement precision
If multiple different assays are used for different therapeutic drugs, then specific detection capability is improved, but standardization and unification are lost, making comparison of immunogenicity difficult
Solution Approach 1:
The device employs a universal bridging assay format that can detect antibodies against multiple different therapeutic drugs using the same detection methodology. The membrane can be configured with capture reagents specific to different drugs, but the overall assay format, detection reagents, and reading methodology remain standardized, enabling both specific detection and cross-drug comparison.
Solution Approach 2:
The patent uses identical detection reagents and assay protocols across different drug-specific tests, creating a standardized 'copy' of the detection methodology that can be applied universally. This allows results from different drug tests to be compared directly, as they all use the same measurement scale and interpretation criteria.
3Reliability
If comprehensive ADA detection is performed, then immunogenicity monitoring is improved, but time consumption and loss of time increase due to complex sample handling and assay procedures
Solution Approach 1:
The device comes pre-configured with all necessary reagents immobilized on the membrane and conjugate pad, and the assay protocol is pre-optimized. Users simply need to apply the sample and wait for the predetermined time for results, eliminating the need for complex sample preparation, reagent mixing, and timing procedures that would otherwise consume significant time.
Solution Approach 2:
The device is designed to perform the entire detection process automatically once the sample is applied. The capillary action drives the sample through the various pads and membrane, the reactions proceed automatically, and the results are self-evident through visual or instrumental reading, requiring minimal user intervention and time investment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The portable devices facilitate standardized ADA testing, enabling effective comparison of immunogenicity, improving patient stratification, therapy monitoring, and postmarketing surveillance, while empowering healthcare decisions and reducing the complexity of current methods.
Implementation Method 1
using lateral flow technology
Implementation Method 2
potentially electrochemiluminescence
Data Source
AI summary
Portable devices for anti-drug antibodies (ADAs) testing are provided. These devices can be used in various applications, including but not restricted to the following: uniform testing of patients for ADAs; selection of therapeutic drug for patient treatment; evaluation of the need to change therapeutic drug or to apply tolerance regimens; selection of patients for clinical trials; comparison of therapeutic drugs marketed for a given disease and also gene therapy; scientific guidance for discovering therapeutic drugs; therapeutic drug development; postmarketing surveillance of therapeutic drugs.